Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen Corporation

Published: Saturday, August 16, 2014
Last Updated: Saturday, August 16, 2014
Bookmark and Share
Addition of lentiviral gene delivery capabilities complements strategic partnering portfolio.

Miltenyi Biotec has announced that it has acquired the lentiviral vector manufacturing business and related assets from US company Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications.

The acquisition further strengthens Miltenyi Biotec’s portfolio in cell and gene therapy. Assets obtained in the transaction include a broad range of intellectual property, process technologies, and cGMP-qualified manufacturing facilities. The Lentigen team will join Miltenyi Biotec, and operate through its newly formed, wholly owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.

Miltenyi Biotec will leverage the combined capabilities by offering customized system and application design in strategic partnerships with clinical investigators and companies to develop and commercialize cell and gene therapies.

“It is our goal at Miltenyi Biotec to become the major supplier of lentiviral vectors for cell and gene therapies, both for clinical research and at commercial scale,” said Stefan Miltenyi, Chief Executive Officer of Miltenyi Biotec. “With the acquisition of the Lentigen assets, we have strengthened our comprehensive portfolio that will enable our current and future partners to proceed in cell therapies efficiently from preclinical testing through human studies to automated manufacturing for widespread commercial therapeutic use, all with a single strategic partner.”

Lentiviral technology provides the most efficient method for delivering genetic material into cells to modulate their function, as demonstrated by recent clinical trials in genetic diseases and oncology indications utilizing lentivirus-modified chimeric antigen receptor (CAR) T cells.

Concurrent with the transaction, the sellers, now operating as Opus Bio, Inc., have been granted certain rights to deploy lentiviral technology in some therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Puttng Cells Through Their Paces
An obstacle course for human lung cells could be the answer for better testing the effectiveness of potential new drugs.
Inherited Heart Condition Breakthrough
Using stem cells, scientists have created a specific heart condition model, yeilding insights into unexpected disease mechanisms.
Genetic Tug of War Before Cells Decide Fate
Researchers report that as developing blood cells are triggered by genetic signals firing on and off, a 'tug of war' occurs.
Origin of Cultured Cells: Not Where You Think
Study shows cultured cells from decades-old cell line does not originate from the patient it was claimed to derive from.
Hope for Zika Treatment Found in Drug Screening
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection.
Worms Point Way Toward Viral Strategies
Rice University wins NIH grant to study how nematodes handle gastrointestinal viruses.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!